社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
SebZz
IP属地：未知
+关注
帖子 · 47
帖子 · 47
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
SebZz
SebZz
·
2021-12-24
Ok
非常抱歉，此主贴已删除
看
2,099
回复
2
点赞
9
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-12-24
Ok
非常抱歉，此主贴已删除
看
2,858
回复
1
点赞
3
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-12-06
Nice
Apple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.<blockquote>KeyBanc表示，苹果股票是一个有吸引力的买入。目标价定为191美元。</blockquote>
Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the
Apple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.<blockquote>KeyBanc表示，苹果股票是一个有吸引力的买入。目标价定为191美元。</blockquote>
看
2,459
回复
评论
点赞
2
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-12-03
Nice
Clover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote>
Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since
Clover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote>
看
2,720
回复
评论
点赞
1
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-12-02
Nice
Novartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote>
Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp
Novartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote>
看
2,233
回复
评论
点赞
3
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-11-30
Evil
非常抱歉，此主贴已删除
看
2,573
回复
评论
点赞
1
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-11-30
Nic3
非常抱歉，此主贴已删除
看
2,690
回复
评论
点赞
3
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-11-29
Nice
非常抱歉，此主贴已删除
看
3,003
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-11-29
Nice
非常抱歉，此主贴已删除
看
3,733
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
SebZz
SebZz
·
2021-11-28
Ok
非常抱歉，此主贴已删除
看
2,483
回复
评论
点赞
3
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3571302905057300","uuid":"3571302905057300","gmtCreate":1608209527730,"gmtModify":1608209527730,"name":"SebZz","pinyin":"sebzz","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":8,"tweetSize":47,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":698827967,"gmtCreate":1640346251244,"gmtModify":1640346251351,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698827967","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":2099,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698827045,"gmtCreate":1640346239313,"gmtModify":1640346239379,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698827045","repostId":"1142015669","repostType":4,"isVote":1,"tweetType":1,"viewCount":2858,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606052903,"gmtCreate":1638802796173,"gmtModify":1638802796260,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606052903","repostId":"1107494736","repostType":4,"repost":{"id":"1107494736","kind":"news","pubTimestamp":1638799191,"share":"https://www.laohu8.com/m/news/1107494736?lang=zh_CN&edition=full","pubTime":"2021-12-06 21:59","market":"us","language":"en","title":"Apple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.<blockquote>KeyBanc表示，苹果股票是一个有吸引力的买入。目标价定为191美元。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107494736","media":"Barrons","summary":"Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the ","content":"<p>Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the stock with a bullish outlook, citing growth in the tech giant’s services segment.</p><p><blockquote>苹果股价周一上涨，此前KeyBanc Capital Markets分析师以这家科技巨头服务领域的增长为由，对该股前景看好。</blockquote></p><p> Analyst Brandon Nispel rated the stock Overweight with a $191 price target. The target presents an 18% increase from Apple’s (ticker: AAPL) $161.84 closing price on Friday. The stock was up 1.2% to $163.73 in premarket trading Monday.</p><p><blockquote>分析师Brandon Nispel将该股跑赢大盘评级为191美元。该目标较苹果（股票代码：AAPL）周五161.84美元的收盘价上涨18%。周一盘前交易中，该股上涨1.2%，至163.73美元。</blockquote></p><p> Of the 42 analysts covering the stock surveyed by FactSet, 32 have it at a Buy or Overweight rating, nine rated it at Hold, and one rated it Underweight.</p><p><blockquote>FactSet调查的42名分析师中，32名分析师给予该股买入或跑赢大盘评级，9名分析师给予持有，1名分析师给予跑输大盘评级。</blockquote></p><p> “While AAPL is expensive by historical valuations, we find AAPL attractive relative to other mega-caps,” Nispel wrote on Monday.</p><p><blockquote>尼斯佩尔周一写道：“虽然从历史估值来看，苹果公司价格昂贵，但我们发现苹果公司相对于其他大型股具有吸引力。”</blockquote></p><p> The analyst outlined three main reasons for his bullish take. Nispel doesn’t believe iPhone unit sales have peaked, with the 5G upgrade cycle potentially pushing Apple past its current peak; he believes the company has managed to increase its product breadth to reduce reliability on iPhone sales; and he foresees services to grow at rates multiple times faster than user growth.</p><p><blockquote>这位分析师概述了他看涨的三个主要原因。Nispel认为iPhone销量尚未见顶，5G升级周期可能会推动苹果超过目前的峰值；他认为，该公司已设法增加其产品广度，以降低iPhone销售的可靠性；他预计服务的增长速度将是用户增长速度的数倍。</blockquote></p><p> The analyst forecasts Apple to have 1.09 billion active iPhones and 1.8 billion active installed devices by the end of the first quarter of the 2022 fiscal year. This presents a 7% and 8% year-over-year increase, respectively.</p><p><blockquote>该分析师预测，到2022财年第一季度末，苹果将拥有10.9亿部活跃iPhone和18亿部活跃安装设备。这分别同比增长7%和8%。</blockquote></p><p> “This shows a healthy growing user base where Apple iPhone market share is low relative to key geographies outside the United States,” Nispel wrote. “As the installed base grows, a larger base can support more sales on lower upgrade rates.”</p><p><blockquote>Nispel写道：“这表明用户群健康增长，相对于美国以外的主要地区，苹果iPhone市场份额较低。”“随着安装基础的增长，更大的基础可以以较低的升级率支持更多的销售。”</blockquote></p><p> Apple’s international segment is likely to grow faster in the coming years as other countries adapt to 5G, prompting a wave of upgrades to compatible hardware, Nispel wrote. He estimates every 1% increase in 5G upgrade rates could drive an incremental 11 million iPhone unit sales.</p><p><blockquote>Nispel写道，随着其他国家适应5G，苹果的国际市场在未来几年可能会增长更快，从而引发一波兼容硬件的升级浪潮。他估计，5G升级率每增加1%，iPhone销量就可能增加1100万部。</blockquote></p><p> As hardware adoption grows, so does Apple’s services business. The segment, which includes services such as Apple TV+, Music, News+, AppleCare, Advertising, and Cloud, has grown 27% in the 2021 fiscal year. Over time, it could become a key profitability driver, growing to more than $100 billion by 2024, Nispel said.</p><p><blockquote>随着硬件采用率的增长，苹果的服务业务也在增长。该部门包括苹果TV+、音乐、News+、AppleCare、广告和云等服务，在2021财年增长了27%。Nispel表示，随着时间的推移，它可能会成为关键的盈利驱动力，到2024年将增长到1000亿美元以上。</blockquote></p><p> Nispel recognized that Apple’s App Store legal battles were concerning, but were “likely more a bend, not break outcome.” The company has had to make modest changes to its App Store guidance in response to court rulings and regulatory changes, including lowering its commission for some developers. It will likely make more concessions over time, such as allowing developers to provide third-party payment options, Nispel said.</p><p><blockquote>尼斯佩尔承认，苹果的应用商店法律诉讼令人担忧，但“可能更多的是一个转变，而不是突破的结果”。该公司不得不对其应用商店指南进行适度修改，以应对法院裁决和监管变化，包括降低一些开发者的佣金。尼斯佩尔表示，随着时间的推移，它可能会做出更多让步，例如允许开发商提供第三方支付选项。</blockquote></p><p> “We expect regulation to take time to implement, and believe Apple’s competitive advantage is unlikely to be substantially harmed,” he added.</p><p><blockquote>“我们预计监管需要时间来实施，并相信苹果的竞争优势不太可能受到实质性损害，”他补充道。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.<blockquote>KeyBanc表示，苹果股票是一个有吸引力的买入。目标价定为191美元。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock Is an Attractive Buy, Says KeyBanc. Price Target Set at $191.<blockquote>KeyBanc表示，苹果股票是一个有吸引力的买入。目标价定为191美元。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-12-06 21:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the stock with a bullish outlook, citing growth in the tech giant’s services segment.</p><p><blockquote>苹果股价周一上涨，此前KeyBanc Capital Markets分析师以这家科技巨头服务领域的增长为由，对该股前景看好。</blockquote></p><p> Analyst Brandon Nispel rated the stock Overweight with a $191 price target. The target presents an 18% increase from Apple’s (ticker: AAPL) $161.84 closing price on Friday. The stock was up 1.2% to $163.73 in premarket trading Monday.</p><p><blockquote>分析师Brandon Nispel将该股跑赢大盘评级为191美元。该目标较苹果（股票代码：AAPL）周五161.84美元的收盘价上涨18%。周一盘前交易中，该股上涨1.2%，至163.73美元。</blockquote></p><p> Of the 42 analysts covering the stock surveyed by FactSet, 32 have it at a Buy or Overweight rating, nine rated it at Hold, and one rated it Underweight.</p><p><blockquote>FactSet调查的42名分析师中，32名分析师给予该股买入或跑赢大盘评级，9名分析师给予持有，1名分析师给予跑输大盘评级。</blockquote></p><p> “While AAPL is expensive by historical valuations, we find AAPL attractive relative to other mega-caps,” Nispel wrote on Monday.</p><p><blockquote>尼斯佩尔周一写道：“虽然从历史估值来看，苹果公司价格昂贵，但我们发现苹果公司相对于其他大型股具有吸引力。”</blockquote></p><p> The analyst outlined three main reasons for his bullish take. Nispel doesn’t believe iPhone unit sales have peaked, with the 5G upgrade cycle potentially pushing Apple past its current peak; he believes the company has managed to increase its product breadth to reduce reliability on iPhone sales; and he foresees services to grow at rates multiple times faster than user growth.</p><p><blockquote>这位分析师概述了他看涨的三个主要原因。Nispel认为iPhone销量尚未见顶，5G升级周期可能会推动苹果超过目前的峰值；他认为，该公司已设法增加其产品广度，以降低iPhone销售的可靠性；他预计服务的增长速度将是用户增长速度的数倍。</blockquote></p><p> The analyst forecasts Apple to have 1.09 billion active iPhones and 1.8 billion active installed devices by the end of the first quarter of the 2022 fiscal year. This presents a 7% and 8% year-over-year increase, respectively.</p><p><blockquote>该分析师预测，到2022财年第一季度末，苹果将拥有10.9亿部活跃iPhone和18亿部活跃安装设备。这分别同比增长7%和8%。</blockquote></p><p> “This shows a healthy growing user base where Apple iPhone market share is low relative to key geographies outside the United States,” Nispel wrote. “As the installed base grows, a larger base can support more sales on lower upgrade rates.”</p><p><blockquote>Nispel写道：“这表明用户群健康增长，相对于美国以外的主要地区，苹果iPhone市场份额较低。”“随着安装基础的增长，更大的基础可以以较低的升级率支持更多的销售。”</blockquote></p><p> Apple’s international segment is likely to grow faster in the coming years as other countries adapt to 5G, prompting a wave of upgrades to compatible hardware, Nispel wrote. He estimates every 1% increase in 5G upgrade rates could drive an incremental 11 million iPhone unit sales.</p><p><blockquote>Nispel写道，随着其他国家适应5G，苹果的国际市场在未来几年可能会增长更快，从而引发一波兼容硬件的升级浪潮。他估计，5G升级率每增加1%，iPhone销量就可能增加1100万部。</blockquote></p><p> As hardware adoption grows, so does Apple’s services business. The segment, which includes services such as Apple TV+, Music, News+, AppleCare, Advertising, and Cloud, has grown 27% in the 2021 fiscal year. Over time, it could become a key profitability driver, growing to more than $100 billion by 2024, Nispel said.</p><p><blockquote>随着硬件采用率的增长，苹果的服务业务也在增长。该部门包括苹果TV+、音乐、News+、AppleCare、广告和云等服务，在2021财年增长了27%。Nispel表示，随着时间的推移，它可能会成为关键的盈利驱动力，到2024年将增长到1000亿美元以上。</blockquote></p><p> Nispel recognized that Apple’s App Store legal battles were concerning, but were “likely more a bend, not break outcome.” The company has had to make modest changes to its App Store guidance in response to court rulings and regulatory changes, including lowering its commission for some developers. It will likely make more concessions over time, such as allowing developers to provide third-party payment options, Nispel said.</p><p><blockquote>尼斯佩尔承认，苹果的应用商店法律诉讼令人担忧，但“可能更多的是一个转变，而不是突破的结果”。该公司不得不对其应用商店指南进行适度修改，以应对法院裁决和监管变化，包括降低一些开发者的佣金。尼斯佩尔表示，随着时间的推移，它可能会做出更多让步，例如允许开发商提供第三方支付选项。</blockquote></p><p> “We expect regulation to take time to implement, and believe Apple’s competitive advantage is unlikely to be substantially harmed,” he added.</p><p><blockquote>“我们预计监管需要时间来实施，并相信苹果的竞争优势不太可能受到实质性损害，”他补充道。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/apple-aapl-stock-attractive-buy-51638798446?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.barrons.com/articles/apple-aapl-stock-attractive-buy-51638798446?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107494736","content_text":"Apple shares were rising Monday after analysts at KeyBanc Capital Markets initiated coverage on the stock with a bullish outlook, citing growth in the tech giant’s services segment.\nAnalyst Brandon Nispel rated the stock Overweight with a $191 price target. The target presents an 18% increase from Apple’s (ticker: AAPL) $161.84 closing price on Friday. The stock was up 1.2% to $163.73 in premarket trading Monday.\nOf the 42 analysts covering the stock surveyed by FactSet, 32 have it at a Buy or Overweight rating, nine rated it at Hold, and one rated it Underweight.\n“While AAPL is expensive by historical valuations, we find AAPL attractive relative to other mega-caps,” Nispel wrote on Monday.\nThe analyst outlined three main reasons for his bullish take. Nispel doesn’t believe iPhone unit sales have peaked, with the 5G upgrade cycle potentially pushing Apple past its current peak; he believes the company has managed to increase its product breadth to reduce reliability on iPhone sales; and he foresees services to grow at rates multiple times faster than user growth.\nThe analyst forecasts Apple to have 1.09 billion active iPhones and 1.8 billion active installed devices by the end of the first quarter of the 2022 fiscal year. This presents a 7% and 8% year-over-year increase, respectively.\n“This shows a healthy growing user base where Apple iPhone market share is low relative to key geographies outside the United States,” Nispel wrote. “As the installed base grows, a larger base can support more sales on lower upgrade rates.”\nApple’s international segment is likely to grow faster in the coming years as other countries adapt to 5G, prompting a wave of upgrades to compatible hardware, Nispel wrote. He estimates every 1% increase in 5G upgrade rates could drive an incremental 11 million iPhone unit sales.\nAs hardware adoption grows, so does Apple’s services business. The segment, which includes services such as Apple TV+, Music, News+, AppleCare, Advertising, and Cloud, has grown 27% in the 2021 fiscal year. Over time, it could become a key profitability driver, growing to more than $100 billion by 2024, Nispel said.\nNispel recognized that Apple’s App Store legal battles were concerning, but were “likely more a bend, not break outcome.” The company has had to make modest changes to its App Store guidance in response to court rulings and regulatory changes, including lowering its commission for some developers. It will likely make more concessions over time, such as allowing developers to provide third-party payment options, Nispel said.\n“We expect regulation to take time to implement, and believe Apple’s competitive advantage is unlikely to be substantially harmed,” he added.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601607958,"gmtCreate":1638517719122,"gmtModify":1638517719122,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601607958","repostId":"1138290638","repostType":4,"repost":{"id":"1138290638","kind":"news","pubTimestamp":1638515006,"share":"https://www.laohu8.com/m/news/1138290638?lang=zh_CN&edition=full","pubTime":"2021-12-03 15:03","market":"us","language":"en","title":"Clover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138290638","media":"TheStreet","summary":"Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since ","content":"<p>Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.</p><p><blockquote>过去几个月，Clover Health的股票一直在苦苦挣扎。随着CLOV的“模因”势头消退，股价自6月初的峰值以来已下跌80%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/528f59c934a300195181e1a4f4dda4a0\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Clover Health logo.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：三叶草健康标志。</span></p></blockquote></p><p> Now, CLOV has hit bottom as shares trade at all-time lows of less than $5. Below, we have listed a few questions that could help determine if now is the time to invest in the stock.</p><p><blockquote>现在，CLOV已触底，股价跌至不到5美元的历史低点。下面，我们列出了一些问题，可以帮助确定现在是否是投资该股票的时候。</blockquote></p><p> <b>The success of Clover Assistant</b></p><p><blockquote><b>三叶草助手的成功</b></blockquote></p><p> AI software platform Clover Assistant is the key differentiator in Clover’s unique model, and it has nearly 100,000 lives under management. The platform was designed to help physicians improve their services and attract new members.</p><p><blockquote>AI软件平台Clover Assistant是Clover独特模型中的关键差异化因素，它管理着近10万条生命。该平台旨在帮助医生改善服务并吸引新会员。</blockquote></p><p> Clover’s business model is heavily dependent on the platform, but experts are skeptical as to whether it can deliver what it promises: ease of use for doctors and money saving opportunities for patients. Clover Assistant has grown 223% YOY and approximately 2,900 health care professionals used Clover Assistant in Q3, up 45% YOY.</p><p><blockquote>Clover的商业模式严重依赖于该平台，但专家们对它能否实现其承诺表示怀疑：医生的易用性和患者的省钱机会。Clover Assistant同比增长223%，第三季度约有2,900名医疗保健专业人员使用Clover Assistant，同比增长45%。</blockquote></p><p> <b>Are bears right?</b></p><p><blockquote><b>熊是对的吗？</b></blockquote></p><p> Known as the “king of SPACs,” Clover saw its stock price plummet earlier this year. The likely culprit: research firm Hindenburgshortedthe stock, claiming that the company was the target of an investigation for dubious sales practices.</p><p><blockquote>被称为“SPAC之王”的Clover今年早些时候股价暴跌。可能的罪魁祸首：研究公司兴登堡做空该股票，声称该公司因可疑销售行为而成为调查目标。</blockquote></p><p> After Hindenburg's bet, CLOV share price plunged 50% year-to-date by the end of May. At that point, the stock caught the attention of Wall Street Bets’ “apes” community and became a target of meme mania. Since early June, stocks spiked 190% but then fell around 80% to all-time lows.</p><p><blockquote>兴登堡下注后，截至5月底，CLOV股价今年迄今暴跌50%。当时，该股引起了华尔街赌注“猿”社区的注意，并成为模因狂热的目标。自6月初以来，股市飙升190%，但随后下跌约80%至历史低点。</blockquote></p><p> Venture capitalist Chamath Palihapitiya, who helped Clover go public through SPAC,defended the company from the allegations. But at that point, it may have been too late: skepticism towards CLOV had spread wide and the stock became a short seller favorite.</p><p><blockquote>帮助Clover通过SPAC上市的风险投资家Chamath Palihapitiya为该公司的指控进行了辩护。但那时，可能已经太晚了：对CLOV的怀疑已经广泛蔓延，该股成为卖空者的最爱。</blockquote></p><p> Currently, short interest is a bit on the hot side: 12% of the float is currently shorted,according to Yahoo Finance. We like to think that anything above 10% is a bearish indicator and a potential short squeeze candidate.</p><p><blockquote>目前，空头兴趣有点偏热：根据雅虎财经的数据，目前12%的流通量被做空。我们倾向于认为任何高于10%的指标都是看跌指标和潜在的轧空候选指标。</blockquote></p><p> <b>CLOV’s path to profitability</b></p><p><blockquote><b>CLOV的盈利之路</b></blockquote></p><p> Clover Health’s “meme” momentum driven by sheer buzz and enthusiasm seems to have lost steam as the main discussion boards “cooled down” on the name. Now, CLOV shares could trade more in line with business fundamentals.</p><p><blockquote>Clover Health由纯粹的嗡嗡声和热情驱动的“迷因”势头似乎已经失去了动力，因为主要讨论板对这个名字的“冷却”。现在，CLOV股票的交易可能会更符合商业基本面。</blockquote></p><p> In that regard, the company has been a strong revenue generator in a market with multi-billion dollar potential: Medicare Advantage. In Q3, Clover generated $472 million in revenues, up an astounding 153% YOY. However, the company is still far from being profitable. Full year 2021 adjusted EBITDA is expected to sit around negative $250 million and $230 million.</p><p><blockquote>在这方面，该公司在具有数十亿美元潜力的市场中一直是强大的收入来源：Medicare Advantage。第三季度，Clover的收入为4.72亿美元，同比增长153%。然而，该公司距离盈利还有很长的路要走。2021年全年调整后EBITDA预计将分别为负2.5亿美元和2.3亿美元。</blockquote></p><p> One key question is how long it may take for Clover to reach profits with the current business model. Another is whether the company will be able to expand outside its current territory. The answers to these questions will likely drive the stock’s performance in the foreseeable future.</p><p><blockquote>一个关键问题是，以目前的商业模式，Clover可能需要多长时间才能实现盈利。另一个问题是该公司是否能够在目前的领土之外扩张。这些问题的答案可能会在可预见的未来推动该股的表现。</blockquote></p><p> Lastly, according to Wall Street experts, CLOV stock is undervalued at current levels. Despite the consensus rating on the stock leaning heavily towards cautious, average price target sits at $8.67, suggesting 76% upside potential from here.</p><p><blockquote>最后，据华尔街专家称，CLOV股票在目前水平上被低估。尽管该股的普遍评级严重倾向于谨慎，但平均目标价仍为8.67美元，表明该股还有76%的上涨潜力。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-12-03 15:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.</p><p><blockquote>过去几个月，Clover Health的股票一直在苦苦挣扎。随着CLOV的“模因”势头消退，股价自6月初的峰值以来已下跌80%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/528f59c934a300195181e1a4f4dda4a0\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Clover Health logo.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：三叶草健康标志。</span></p></blockquote></p><p> Now, CLOV has hit bottom as shares trade at all-time lows of less than $5. Below, we have listed a few questions that could help determine if now is the time to invest in the stock.</p><p><blockquote>现在，CLOV已触底，股价跌至不到5美元的历史低点。下面，我们列出了一些问题，可以帮助确定现在是否是投资该股票的时候。</blockquote></p><p> <b>The success of Clover Assistant</b></p><p><blockquote><b>三叶草助手的成功</b></blockquote></p><p> AI software platform Clover Assistant is the key differentiator in Clover’s unique model, and it has nearly 100,000 lives under management. The platform was designed to help physicians improve their services and attract new members.</p><p><blockquote>AI软件平台Clover Assistant是Clover独特模型中的关键差异化因素，它管理着近10万条生命。该平台旨在帮助医生改善服务并吸引新会员。</blockquote></p><p> Clover’s business model is heavily dependent on the platform, but experts are skeptical as to whether it can deliver what it promises: ease of use for doctors and money saving opportunities for patients. Clover Assistant has grown 223% YOY and approximately 2,900 health care professionals used Clover Assistant in Q3, up 45% YOY.</p><p><blockquote>Clover的商业模式严重依赖于该平台，但专家们对它能否实现其承诺表示怀疑：医生的易用性和患者的省钱机会。Clover Assistant同比增长223%，第三季度约有2,900名医疗保健专业人员使用Clover Assistant，同比增长45%。</blockquote></p><p> <b>Are bears right?</b></p><p><blockquote><b>熊是对的吗？</b></blockquote></p><p> Known as the “king of SPACs,” Clover saw its stock price plummet earlier this year. The likely culprit: research firm Hindenburgshortedthe stock, claiming that the company was the target of an investigation for dubious sales practices.</p><p><blockquote>被称为“SPAC之王”的Clover今年早些时候股价暴跌。可能的罪魁祸首：研究公司兴登堡做空该股票，声称该公司因可疑销售行为而成为调查目标。</blockquote></p><p> After Hindenburg's bet, CLOV share price plunged 50% year-to-date by the end of May. At that point, the stock caught the attention of Wall Street Bets’ “apes” community and became a target of meme mania. Since early June, stocks spiked 190% but then fell around 80% to all-time lows.</p><p><blockquote>兴登堡下注后，截至5月底，CLOV股价今年迄今暴跌50%。当时，该股引起了华尔街赌注“猿”社区的注意，并成为模因狂热的目标。自6月初以来，股市飙升190%，但随后下跌约80%至历史低点。</blockquote></p><p> Venture capitalist Chamath Palihapitiya, who helped Clover go public through SPAC,defended the company from the allegations. But at that point, it may have been too late: skepticism towards CLOV had spread wide and the stock became a short seller favorite.</p><p><blockquote>帮助Clover通过SPAC上市的风险投资家Chamath Palihapitiya为该公司的指控进行了辩护。但那时，可能已经太晚了：对CLOV的怀疑已经广泛蔓延，该股成为卖空者的最爱。</blockquote></p><p> Currently, short interest is a bit on the hot side: 12% of the float is currently shorted,according to Yahoo Finance. We like to think that anything above 10% is a bearish indicator and a potential short squeeze candidate.</p><p><blockquote>目前，空头兴趣有点偏热：根据雅虎财经的数据，目前12%的流通量被做空。我们倾向于认为任何高于10%的指标都是看跌指标和潜在的轧空候选指标。</blockquote></p><p> <b>CLOV’s path to profitability</b></p><p><blockquote><b>CLOV的盈利之路</b></blockquote></p><p> Clover Health’s “meme” momentum driven by sheer buzz and enthusiasm seems to have lost steam as the main discussion boards “cooled down” on the name. Now, CLOV shares could trade more in line with business fundamentals.</p><p><blockquote>Clover Health由纯粹的嗡嗡声和热情驱动的“迷因”势头似乎已经失去了动力，因为主要讨论板对这个名字的“冷却”。现在，CLOV股票的交易可能会更符合商业基本面。</blockquote></p><p> In that regard, the company has been a strong revenue generator in a market with multi-billion dollar potential: Medicare Advantage. In Q3, Clover generated $472 million in revenues, up an astounding 153% YOY. However, the company is still far from being profitable. Full year 2021 adjusted EBITDA is expected to sit around negative $250 million and $230 million.</p><p><blockquote>在这方面，该公司在具有数十亿美元潜力的市场中一直是强大的收入来源：Medicare Advantage。第三季度，Clover的收入为4.72亿美元，同比增长153%。然而，该公司距离盈利还有很长的路要走。2021年全年调整后EBITDA预计将分别为负2.5亿美元和2.3亿美元。</blockquote></p><p> One key question is how long it may take for Clover to reach profits with the current business model. Another is whether the company will be able to expand outside its current territory. The answers to these questions will likely drive the stock’s performance in the foreseeable future.</p><p><blockquote>一个关键问题是，以目前的商业模式，Clover可能需要多长时间才能实现盈利。另一个问题是该公司是否能够在目前的领土之外扩张。这些问题的答案可能会在可预见的未来推动该股的表现。</blockquote></p><p> Lastly, according to Wall Street experts, CLOV stock is undervalued at current levels. Despite the consensus rating on the stock leaning heavily towards cautious, average price target sits at $8.67, suggesting 76% upside potential from here.</p><p><blockquote>最后，据华尔街专家称，CLOV股票在目前水平上被低估。尽管该股的普遍评级严重倾向于谨慎，但平均目标价仍为8.67美元，表明该股还有76%的上涨潜力。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/memestocks/clov/clov-stock-has-hit-rock-bottom-time-to-buy\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://www.thestreet.com/memestocks/clov/clov-stock-has-hit-rock-bottom-time-to-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138290638","content_text":"Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.\nFigure 1: Clover Health logo.\nNow, CLOV has hit bottom as shares trade at all-time lows of less than $5. Below, we have listed a few questions that could help determine if now is the time to invest in the stock.\nThe success of Clover Assistant\nAI software platform Clover Assistant is the key differentiator in Clover’s unique model, and it has nearly 100,000 lives under management. The platform was designed to help physicians improve their services and attract new members.\nClover’s business model is heavily dependent on the platform, but experts are skeptical as to whether it can deliver what it promises: ease of use for doctors and money saving opportunities for patients. Clover Assistant has grown 223% YOY and approximately 2,900 health care professionals used Clover Assistant in Q3, up 45% YOY.\nAre bears right?\nKnown as the “king of SPACs,” Clover saw its stock price plummet earlier this year. The likely culprit: research firm Hindenburgshortedthe stock, claiming that the company was the target of an investigation for dubious sales practices.\nAfter Hindenburg's bet, CLOV share price plunged 50% year-to-date by the end of May. At that point, the stock caught the attention of Wall Street Bets’ “apes” community and became a target of meme mania. Since early June, stocks spiked 190% but then fell around 80% to all-time lows.\nVenture capitalist Chamath Palihapitiya, who helped Clover go public through SPAC,defended the company from the allegations. But at that point, it may have been too late: skepticism towards CLOV had spread wide and the stock became a short seller favorite.\nCurrently, short interest is a bit on the hot side: 12% of the float is currently shorted,according to Yahoo Finance. We like to think that anything above 10% is a bearish indicator and a potential short squeeze candidate.\nCLOV’s path to profitability\nClover Health’s “meme” momentum driven by sheer buzz and enthusiasm seems to have lost steam as the main discussion boards “cooled down” on the name. Now, CLOV shares could trade more in line with business fundamentals.\nIn that regard, the company has been a strong revenue generator in a market with multi-billion dollar potential: Medicare Advantage. In Q3, Clover generated $472 million in revenues, up an astounding 153% YOY. However, the company is still far from being profitable. Full year 2021 adjusted EBITDA is expected to sit around negative $250 million and $230 million.\nOne key question is how long it may take for Clover to reach profits with the current business model. Another is whether the company will be able to expand outside its current territory. The answers to these questions will likely drive the stock’s performance in the foreseeable future.\nLastly, according to Wall Street experts, CLOV stock is undervalued at current levels. Despite the consensus rating on the stock leaning heavily towards cautious, average price target sits at $8.67, suggesting 76% upside potential from here.","news_type":1,"symbols_score_info":{"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":2720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603567349,"gmtCreate":1638429661733,"gmtModify":1638429661852,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603567349","repostId":"1159695915","repostType":4,"repost":{"id":"1159695915","kind":"news","pubTimestamp":1638429346,"share":"https://www.laohu8.com/m/news/1159695915?lang=zh_CN&edition=full","pubTime":"2021-12-02 15:15","market":"us","language":"en","title":"Novartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1159695915","media":"Marketwatch","summary":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp","content":"<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p><p><blockquote>诺华公司周四在今天晚些时候开始的研发日之前表示，预计销售额将在中期保持增长，这主要归功于其主要的市场内增长动力，同时到2026年可能会批准几项新资产。</blockquote></p><p> The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p><p><blockquote>这家瑞士制药巨头表示，在其药物Cosentyx、Entresto、Kesimpta、Zolgensma、Kisqali和Leqvio数十亿美元销售额的推动下，到2026年，销售额应继续以至少4%的复合年增长率增长。</blockquote></p><p> \"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p><p><blockquote>诺华首席执行官Vas Narasimhan表示：“到2026年，可能会批准多达20项具有巨大销售潜力的新资产，这将推动下一阶段的增长并解决主要未满足的需求。”</blockquote></p><p> Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p><p><blockquote>诺华还表示，其销售额最大的药物Cosentyx在两项名为Sunrise和Sunshine的3期研究中达到了主要疗效终点，在这些研究中，患者接受了中度至重度化脓性汗腺炎（一种慢性皮肤病）的治疗。</blockquote></p><p></p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Marketwatch</strong><span class=\"h-time small\">2021-12-02 15:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p><p><blockquote>诺华公司周四在今天晚些时候开始的研发日之前表示，预计销售额将在中期保持增长，这主要归功于其主要的市场内增长动力，同时到2026年可能会批准几项新资产。</blockquote></p><p> The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p><p><blockquote>这家瑞士制药巨头表示，在其药物Cosentyx、Entresto、Kesimpta、Zolgensma、Kisqali和Leqvio数十亿美元销售额的推动下，到2026年，销售额应继续以至少4%的复合年增长率增长。</blockquote></p><p> \"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p><p><blockquote>诺华首席执行官Vas Narasimhan表示：“到2026年，可能会批准多达20项具有巨大销售潜力的新资产，这将推动下一阶段的增长并解决主要未满足的需求。”</blockquote></p><p> Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p><p><blockquote>诺华还表示，其销售额最大的药物Cosentyx在两项名为Sunrise和Sunshine的3期研究中达到了主要疗效终点，在这些研究中，患者接受了中度至重度化脓性汗腺炎（一种慢性皮肤病）的治疗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">Marketwatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1159695915","content_text":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.\nThe Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.\n\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.\nNovartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.","news_type":1,"symbols_score_info":{"NVS":0.9}},"isVote":1,"tweetType":1,"viewCount":2233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609958605,"gmtCreate":1638233759561,"gmtModify":1638233759645,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Evil","listText":"Evil","text":"Evil","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609958605","repostId":"2187309641","repostType":4,"isVote":1,"tweetType":1,"viewCount":2573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609951321,"gmtCreate":1638233680704,"gmtModify":1638233688949,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nic3","listText":"Nic3","text":"Nic3","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609951321","repostId":"1122315710","repostType":2,"isVote":1,"tweetType":1,"viewCount":2690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600248704,"gmtCreate":1638164444630,"gmtModify":1638164444630,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600248704","repostId":"1129316714","repostType":4,"isVote":1,"tweetType":1,"viewCount":3003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600248241,"gmtCreate":1638164393395,"gmtModify":1638164393395,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600248241","repostId":"2187327727","repostType":4,"isVote":1,"tweetType":1,"viewCount":3733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600335037,"gmtCreate":1638065477252,"gmtModify":1638065477252,"author":{"id":"3571302905057300","authorId":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571302905057300","authorIdStr":"3571302905057300"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600335037","repostId":"2186287173","repostType":4,"isVote":1,"tweetType":1,"viewCount":2483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}